Royalty Pharma
RPRX
$0.35 (1.25%)
1D
1W
3M
1Y
5Y
ALL
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 2 hours ago • RPRX
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue EstimatesGlobeNewsWire • 4 hours ago • RPRX
Royalty Pharma to Acquire Royalty Interest in Sanofi's FrexalimabZacks Investment Research • 1 day ago • RPRX
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)Zacks Investment Research • 3 days ago • RPRX
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key MetricsZacks Investment Research • 7 days ago • RPRX
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.